Found the last paragraph incredibly interesting.
It seemed unnecessary, but necessary at the same time. Shows they are feeling some heat from the SP, but trying to exert their control.
It was almost full of frustration at being questioned as to their direction - no matter the SP being skinned.
Also found their comment that the clear plan the board has developed over last 12 months has meant that we now require less capital (than would have been the case without the marvellous efforts of the board!).
I'm thinking a $2m raise at 0.2c for about a 41% dilution. Feels yuck writing that.
Still, sounds as though commercial partners are wanting data data data, and i have always liked that ALT is a data driven business.. through to creating best of breed product to stay ahead of the competition. Providing the clinical trial can prove up the product to the necessary requirements of the some big globals, there is still plenty of value here for shareholders - just not the 200 bagger once envisaged
